- Home
- OCS
as 05-20-2024 11:32am EST
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 544.4M | IPO Year: | N/A |
| Target Price: | $30.20 | AVG Volume (30 days): | 41.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.05 - $14.50 | Next Earning Date: | 05-08-2024 |
| Revenue: | $995,455 | Revenue Growth: | -1.02% |
| Revenue Growth (this year): | 4.64% | Revenue Growth (next year): | 176.73% |
Share on Social Networks:
Latest Oculis Holding AG Ordinary shares News
OCS Breaking Stock News: Dive into OCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Oculis updates share capital for its existing at-the-market offering program
GlobeNewswire
12 days ago
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
GlobeNewswire
12 days ago
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
GlobeNewswire
12 days ago
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
GlobeNewswire
13 days ago
Oculis Publishes Invitation to the Annual General Meeting
GlobeNewswire
14 days ago
Oculis to Present at Bank of America Global Healthcare Conference
GlobeNewswire
21 days ago
Oculis Publishes Invitation to the Annual General Meeting
GlobeNewswire
a month ago